1

How Milligram users log it

Track your protocol with Milligram.

12%The 5th most tracked compound in Milligram: of people who track compounds in Milligram logged MOTS-c in the last 90 days.

Schedule

  1. Daily23%
  2. Every other day42%
  3. Twice a week25%
  4. Weekly8%
  5. Less often2%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 1.4 and 5 mg per dose; the median was 2.5 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging MOTS-c who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA.1 FDA's briefing credits Lee and collaborators as the first to sequence it, in a 2015 Cell Metabolism paper whose authors report mouse and cell experiments in which MOTS-c treatment in mice "prevented age-dependent and high-fat diet-induced insulin resistance, as well as diet-induced obesity".1,3 Two of that paper's authors declare ties to CohBar, Inc.: "P.C. is a stockholder of and consultant for, and C.L. is a consultant for CohBar, Inc.".3 The app grades the evidence for MOTS-c as emerging.

In its briefing document for the July 2026 meeting of its Pharmacy Compounding Advisory Committee, FDA states: "we did not identify data, such as clinical studies, evaluating the administration of MOTS-c to humans".1 A search of Europe PMC on 16 November 2026 for MOTS-c with randomized, placebo-controlled, phase 1 or clinical trial in the summary text returned 4 records. Their titles concern metformin treatment in breast cancer (Cuyas 2022), exercise (von Walden 2021 and Dieli-Conwright 2021) and outcome prediction in type 2 diabetes (Ikonomidis 2020), and none reports giving MOTS-c. The pharmacology of injected MOTS-c comes from rodent and cell experiments, which FDA describes as "limited to in-vitro and in-vivo rodent models".1

Metabolic signalling in mice and cells

Lee and colleagues reported in 2015 that MOTS-c's "cellular actions inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to AMPK activation".3 In cells engineered to overexpress MOTS-c, endogenous AICAR rose "to levels higher than 20-fold" compared with control cells.3 On the organ involved, the authors write: "Its primary target organ appears to be the skeletal muscle".3

Nuclear signalling

Kim and colleagues reported in cell experiments in 2018 that MOTS-c "translocates to the nucleus and regulates nuclear gene expression following metabolic stress" in an AMPK-dependent manner.7

What FDA says about the mechanism

FDA's briefing states that "the molecular mechanisms by which MOTS-c increases AMPK signaling remain poorly understood".1 It adds that "the molecular targets underlying the pharmacological effects of MOTS-c remain unknown".1 The authors of the 2015 and 2018 papers declare ties to CohBar, Inc.: "P.C. is a stockholder of and consultant for, and C.L. is a consultant for CohBar, Inc." in 2015, and "C.L. is a consultant for and a shareholder of CohBar, Inc." in 2018.3,7

A genetic variant discussed in a longevity commentary

In a 2015 commentary in Aging Cell, Fuku and colleagues wrote of a polymorphism "specific for the Northeast Asian population" in the MOTS-c-encoding mitochondrial DNA, m.1382A>C, that "may be among the putative biological mechanisms explaining the high longevity of Japanese people", adding "Although more research is needed".8

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~2 h
Bioavailability
95%
Typical dose
5–10 mg
Route
SubQ
Time to peak
~30 min

FDA's briefing states that it "did not identify in-vivo pharmacokinetic or toxicokinetic studies of MOTS-c" and that it "did not identify clinical studies that provided pharmacokinetic data for MOTS-c-related BDSs".1 The figures in the table below are the app's own and are shown beside what the sources report.

Table 4.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 2 hoursNo half-life study reported; in human whole blood in vitro, MOTS-c broke down rapidly into shorter peptides1
Bioavailability95% by subcutaneous injectionNo bioavailability figure reported1
Time to peakAbout 30 minutesNo time to peak reported1
Duration of activityAbout 168 hours (7 days)No duration reported1

The only pharmacokinetic-related study FDA identified was an in vitro experiment by Knoop and colleagues of the German Sport University Cologne, published in 2019, in which human whole blood was incubated with MOTS-c at 37°C for 15 or 60 minutes.1,9 The authors identified shorter peptides in the blood and, in FDA's summary, "stated that in-vitro proteolytic hydrolysis of MOTS-c into the shorter peptides was rapid and did not require its long incubation with human blood".1 FDA adds: "It remains to be determined whether exogenous administration of MOTS-c to humans can generate pharmacologically active concentrations of the peptide over time".1

Circulating MOTS-c values differ between the studies that measured them. Knoop and colleagues reported 45.9 to 218.5 ng/mL by ELISA in 20 healthy people, which "could not be confirmed by LC/MS", with a lower limit of detection of 100 pg/mL for the mass spectrometry method.9 Cataldo and colleagues reported plasma concentrations of 0.48 ng/mL in lean and 0.52 ng/mL in obese people, and Du and colleagues reported 561.64 ng/mL in control children and adolescents and 472.61 ng/mL in obese ones.10,6

5

Human studies

None of the human reports below gave MOTS-c as a treatment: they measured people's own MOTS-c levels, apart from a registered phase 1 trial of CB4211, which a review describes as a MOTS-c analog.11

Table 5.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Qin and colleagues, 201812Two groups compared (n=20 each); plasma sampled at catheterization40 patients with recurrent angina and no structural coronary lesions: 20 with normal endothelial function, 20 with endothelial dysfunctionNo MOTS-c given to the patients; a separate experiment used 2 µg/ml MOTS-c on rat and mouse aortic ringsPlasma MOTS-c was lower in patients with endothelial dysfunction (p=0.007).
Cataldo and colleagues, 201810Lean and obese groups compared (n=10 per group)10 lean and 10 obese peopleNo MOTS-c given; blood measurement onlyPlasma MOTS-c was similar in lean and obese people (0.48±0.16 and 0.52±0.15 ng/mL; p=0.60) and correlated with HOMA (r=0.53; p<0.05) and Matsuda index (r=-0.46; p<0.05); within groups, the associations remained only in lean individuals.
Du and colleagues, 20186Case-control study, recruited in Hubei Province, China, in 201740 obese children and adolescents (27 males) and 57 controls (40 males)No MOTS-c given; blood measurement onlyMOTS-c was lower in the obese group (472.61 ±22.83 vs 561.64 ±19.19 ng/mL, P <.01) and in obese males (465.26 ±24.53 vs 584.07 ±21.18 ng/mL, P <.001), but comparable in females (P >.05).
Ramanjaneya and colleagues, 20195Cross-sectional study in Qatar225 people: 68 normal, 33 with prediabetes, 31 with type 2 diabetes and HbA1c under 7%, 93 with HbA1c over 7%No MOTS-c given; serum measurement onlySerum MOTS-c was lower in type 2 diabetes than in controls (p < 0.007) and correlated negatively with age (p < 0.002), HbA1c (p < 0.001) and glucose (p < 0.002) and positively with BMI (p < 0.035), total cholesterol (p < 0.0001) and LDL (p < 0.001).
D'Souza and colleagues, 202013Young, middle-aged and older men compared; plasma and muscle104 healthy males in four groups of 26: young (18 to 30 years), middle-aged (45 to 55) and two older groups (70 to 81); plasma and muscle of the older men came from different participantsNo MOTS-c given; plasma sampled after an overnight fastPlasma MOTS-c was lower by 11% (middle-aged) and 21% (older) than in the young group, while older and middle-aged men had about 1.5-fold higher muscle MOTS-c expression.
Reynolds and colleagues, 20214Paired before-and-after sampling around one exercise session10 sedentary healthy young men, 24.5 ± 3.7 yearsNo MOTS-c given; stationary bicycle exercise, samples before, during and after, and after a 4-hour restMuscle MOTS-c rose 11.9-fold after exercise (P = 0.0098); circulating MOTS-c rose 1.6-fold during and 1.5-fold after exercise (P = 0.0011 and 0.0021) and returned to baseline after 4 hours of rest.
von Walden and colleagues, 202114Randomised exercise study with a control group30 people: 10 endurance exercise, 10 resistance exercise, 10 controlNo MOTS-c given; endurance: 45 min cycling at 70% of estimated VO2max; resistance: 4 sets × 7RM, leg press and knee extension; blood and muscle samples before and at 30 minutes and 3 hoursHumanin rose significantly after endurance exercise but not resistance exercise, and "MOTS-C levels showed a trend to increase after EE".
CohBar, NCT03998514, 2018 to 202115Phase 1, randomised, double-blind, placebo-controlled, in three parts; sponsor CohBar, Inc.88 enrolled; healthy non-obese people (parts A and B) and people with NAFLD (part C)CB4211, which a review calls a MOTS-c analog, by subcutaneous injection: single doses (A), once daily for 7 days (B) and once daily for 28 days (C); doses not stated in the entryPrimary outcomes are adverse events and safety measures; no results are posted in the entry.

A search of Europe PMC on 16 November 2026 for CB4211 returned 10 records, none with a title reporting a trial of CB4211. A 2022 review by Miller and colleagues states that CB4211 "has been posed as a therapeutic target in clinical trials for nonalcoholic steatohepatitis and obesity".11 One of its authors declares: "PC is an advisor to and stockholder in CohBar Inc. UCLA has licensed the intellectual property on humanin, MOTS-c, and SHLPs, on which PC is listed as an inventor, to CohBar.".11

Deeper analysis: Reynolds and colleagues, Nature Communications, 2021

Reynolds and colleagues sampled 10 sedentary healthy young men on a stationary bicycle and measured MOTS-c in skeletal muscle by western blot and in blood by ELISA.4 They report that "exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation".4 The same paper treated mice with MOTS-c and reports that it "can significantly enhance physical performance in young (2 mo.), middle-age (12 mo.), and old (22 mo.) mice".4 In young CD-1 mice given 5 or 15 mg/kg/day intraperitoneally (5 to 6 per group), running capacity was higher on the higher dose after 10 days of treatment but not after 7 days, and the final treadmill stage was reached by 100% of mice on the higher dose and by 16.6% on the lower dose and in the control group. The text describes these mice as fed a high-fat diet, while the figure legend for the same panels says normal diet.4 In male mice that had 8 weeks of daily injections and then three injections a week at 15 mg/kg/day from 23.5 months of age, the authors report "a trend towards increased median (6.4%) and maximum (7.0%) lifespan and reduced hazard ratio (0.654)", with an overall curve difference of P = 0.23.4 The authors write that "Larger cohorts will be needed to confirm the broader significance of MOTS-c treatment on overall longevity".4 Funding came from the American Federation for Aging Research, the US National Institute on Aging and other bodies, and the competing-interests statement reads: "P.C. and C.L. are consultants and shareholders of CohBar, Inc".4

Deeper analysis: Lee and colleagues, Cell Metabolism, 2015

Lee and colleagues gave 8-week-old male CD-1 mice on a high-fat diet (60% of calories from fat) MOTS-c at 0.5 mg/kg/day intraperitoneally for 8 weeks, with 10 mice per group.3 They report that "MOTS-c treatment had no effect on body weight in mice fed a normal diet" but "remarkably prevented obesity when administrated to mice fed a HFD", with identical caloric intake between the groups.3 In clamp experiments in high-fat-fed C57BL/6 mice given 5 mg/kg/day intraperitoneally for 7 days, with 6 to 8 mice per group, the authors report enhanced insulin-stimulated glucose disposal "indicative of enhanced skeletal muscle insulin sensitivity, but the rate of hepatic glucose production (HGP) was comparable between the groups".3 The authors suggest that "derivatives of this molecule might be useful in ameliorating the abnormal metabolism associated with aging in humans".3 The paper's funding statement lists "UCSD-UCLA Diabetes Research Center grant (NIH DK063491), a Glenn Foundation Award" and further NIH and foundation grants, and it declares the CohBar ties above.3

Deeper analysis: FDA evaluation, July 2026

FDA reviewers evaluated MOTS-c (free base) and MOTS-c acetate after a nomination by Wells Pharmacy Network, which was withdrawn, and FDA evaluated them "at its discretion".1 The nominated uses were insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity, in 5 mg and 10 mg subcutaneous injection products.1 The briefing states that "The nominator has not provided clinical evidence on the use of MOTS-c-related BDSs" and that the nomination cited 12 literature references, which "did not include clinical studies".1 FDA's own stated limits on the nonclinical studies are that they "have been restricted to rodent models and have not assessed dose-response relationships".1 It also notes that the studies "do not clearly identify the specific form of MOTS-c (free base or salt) used".1

6

Doses reported in studies

No dose of MOTS-c given to people is reported in the sources, and FDA found no clinical study of it.1 The app lists a typical dose of 5 to 10 mg, a range that spans the 5 mg and 10 mg strengths FDA describes in the withdrawn nomination, not a dose from a study.1 The first five rows of the table are doses given in animal studies, all by intraperitoneal injection; the last row is a product proposed for people.

A phase 2a study of MOTS-c registered in 2026 (NCT07505745), recruiting when read, plans a fixed dose by subcutaneous injection once daily for 12 weeks; the registry entry gives no dose amount.20

Table 6.1Doses reported in studies6 rows
StudyAnimalsDoseLengthResult
Lee and colleagues, 2015Male CD-1 mice on a high-fat diet0.5 mg/kg/day8 weeksObesity prevented on a high-fat diet, per the authors3
Lee and colleagues, 2015Male C57BL/6 mice on a high-fat diet; soleus muscle from 3 and 12 month old mice5 mg/kg/day7 daysInsulin sensitivity measured by clamp and by muscle glucose uptake3
Kim and colleagues, 2019Diet-induced obese mice2.5 mg/kg twice a day3 daysThree plasma metabolite pathways were reduced; co-author Pinchas Cohen is a consultant and stockholder of CohBar Inc.16
Reynolds and colleagues, 2021Young CD-1 mice, 5 to 6 per group; high-fat diet per the text, normal diet per the figure legend5 or 15 mg/kg/day10 daysHigher running capacity at 15 mg/kg/day after 10 days, not after 7 days4
Reynolds and colleagues, 2021Male C57BL/6N mice; 8 weeks of daily injections, then 3 times a week from 23.5 months of age15 mg/kg/day, 3 times a weekFollowed for lifespanMedian lifespan trend of 6.4%, P = 0.23 overall4
Withdrawn nomination, as described by FDAProposed product for people, not a study5 mg and 10 mg strengths, subcutaneous injectionNot statedNo clinical study cited by the nominator1
7

Side effects reported

No study in the sources reports side effects of MOTS-c given to people.1 FDA's Office of Surveillance and Epidemiology searched its FAERS adverse event database for MOTS-c reports through 28 February 2024 and from 26 February 2024 through 9 March 2025, and "The searches retrieved no reports".1 FDA notes that "Unless an adverse event report is submitted to FDA, the Agency may not be aware of adverse events associated with a product compounded under section 503A".1 FDA also did not identify nonclinical toxicity studies of MOTS-c.1

On immunogenicity, FDA states: "FDA is concerned about potential for immunogenicity when administered by an injection ROA as proposed", because of potential aggregation and peptide-related impurities.1 It adds that there "are insufficient data to conclude that MOTS-c-related BDSs do not present these risks".1

The app lists blood glucose, HbA1c and body weight as markers. In the human reports above these measures were compared with circulating MOTS-c, not changed by giving it, and the associations differ between studies. Ramanjaneya and colleagues found a positive correlation with BMI (p < 0.035) and negative correlations with HbA1c (p < 0.001) and glucose (p < 0.002) in 225 people.5 Du and colleagues found levels negatively correlated with body mass index, fasting insulin, HOMA-IR and HbA1c in the male children and adolescents.6 Cataldo and colleagues, with 10 people per group, concluded that "plasma MOTS-c concentration is unaltered in human obesity" and that "MOTS-c associates positively with insulin resistance mostly in lean individuals".10

In mice, the 2015 Lee paper reports that treatment "prevented HFD-induced hyperinsulinemia, indicating improved glucose homeostasis".3 Reynolds and colleagues report that "non-fasting blood glucose was better maintained in LLII MOTS-c-treated old mice".4

FDA states that there is no applicable United States Pharmacopeia or National Formulary monograph for MOTS-c (free base) or its acetate form and that "neither is a component of an FDA-approved drug".1 FDA's category 2 page lists MOTs-C in its table headed "Bulk drug substances nominated but withdrawn", with the statement that "FDA has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration".17

FDA's briefing concludes: "we propose not adding MOTS-c (free base) or MOTS-c acetate to the 503A Bulks List".1 The advisory committee considered MOTS-c on 23 July 2026.18 Healio reported that the committee voted on placing the substances on the 503A bulks list and that "The last votes on Thursday for MOTS-c in free base and acetate forms both passed 7-5-2", which reads as 7 in favour, 5 against and 2 abstaining; the tally comes from a news report, not an official record.19 One of the two abstaining members, Christian, is quoted: "I don't have enough to make a decision on this one".19 Among the votes against, Healio reports that Rebello cited concerns about data efficacy and safety "related to injectable drugs" and that Zamboni cited a "lack of fundamental information to evaluate the drug".19 The committee's role is advisory: FDA states that its briefing package exists "to obtain the advisory committee's advice" and that "The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized".1 Healio lists the uses discussed for MOTS-c as osteoporosis and obesity, while FDA's briefing lists six nominated uses and states that it "did not evaluate the proposed uses".19,1

The World Anti-Doping Agency's 2026 Prohibited List names MOTS-c in class S4.4.1 of the metabolic modulators, among "Activators of the AMP-activated protein kinase (AMPK)".2 Section S4 is "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and substances in classes S4.3 and S4.4 are non-specified substances.2 Knoop and colleagues of the German Sport University Cologne developed a mass spectrometry method for MOTS-c in plasma and wrote that "it appears advisable to monitor the potential use of synthetic MOTS-c in sports".9

The sources do not report a half-life, time to peak, bioavailability or dose of MOTS-c in people, and FDA states that the nominator and FDA identified no pharmacokinetic study in animals or people.1 FDA writes that "the clinical relevance of the findings of these nonclinical studies is currently unknown".1 Whether CB4211, which a review calls a MOTS-c analog, behaves like MOTS-c in people is not addressed in the registry entry, which posts no results.15,11 The circulating levels measured in different studies differ, as the Knoop, Cataldo and Du values above show.9,10,6

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA.1 Lee and colleagues described it in Cell Metabolism in 2015, and the authors report that in their mouse experiments MOTS-c treatment prevented age-dependent and high-fat diet-induced insulin resistance.3 Two of the authors declare ties to CohBar, Inc.3

What is the half-life of MOTS-c?

No measured half-life of MOTS-c is reported in the sources, and the app lists about 2 hours. FDA identified no pharmacokinetic study in animals or people, and one in vitro experiment found that MOTS-c in human whole blood was rapidly hydrolysed into shorter peptides.1

Is MOTS-c banned by WADA?

Yes, for athletes under the World Anti-Doping Code: the WADA 2026 Prohibited List names MOTS-c in class S4.4.1, among activators of AMPK, in a section prohibited at all times.2

Is MOTS-c approved by the FDA?

No: FDA states that MOTS-c (free base) and MOTS-c acetate are not components of an FDA-approved drug.1 FDA proposed that neither be added to the 503A Bulks List, and Healio reported that the committee's votes on placing MOTS-c free base and acetate on that list each passed 7-5-2 (7 in favour, 5 against, 2 abstaining) on 23 July 2026, with FDA's final determination still to come.1,18,19

Has MOTS-c been tested in humans?

FDA states that it did not identify clinical studies evaluating the administration of MOTS-c to humans.1 Human studies in the sources measured people's own MOTS-c levels, for example after exercise, and a phase 1 trial of CB4211, which a review calls a MOTS-c analog, is registered without posted results.4,15

How does MOTS-c work?

In mouse and cell experiments, MOTS-c activates AMPK, and the 2015 paper reports that its cellular actions inhibit the folate cycle and de novo purine biosynthesis.3 FDA states that the molecular targets underlying its effects remain unknown.1

What are the side effects of MOTS-c?

No clinical study in the sources reports side effects of MOTS-c, and FDA's adverse event database searches through 9 March 2025 retrieved no reports.1 FDA states that it is concerned about immunogenicity with injection and that potential safety risks in humans are unknown.1

What doses of MOTS-c were used in studies?

No dose given to people is reported in the sources. Mouse studies injected 0.5, 2.5, 5 and 15 mg/kg intraperitoneally, for example 0.5 mg/kg/day for 8 weeks in the 2015 Lee paper.3,16,4

Do MOTS-c levels fall with age?

In one study of 104 healthy men (26 per group), circulating MOTS-c was lower by 11% in middle-aged and 21% in older men than in young men, while muscle MOTS-c expression was about 1.5-fold higher; the authors note that the older men's plasma and muscle samples came from different participants, which limits that comparison.13 In mice, Lee and colleagues reported that MOTS-c levels in muscle and serum declined between 4 and 32 months of age (3 to 4 mice per age).3

13

References

  1. US Food and Drug Administration. Evaluation of MOTS-c-related bulk drug substances (MOTS-c (free base) and MOTS-c acetate) for inclusion on the 503A bulk drug substances list. Briefing document, Pharmacy Compounding Advisory Committee, 23 to 24 July 2026. FDA briefing document
  2. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
  3. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015. PMC4350682
  4. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021. PMC7817689
  5. Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne) 2019. PMC6554664
  6. Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes 2018. PMID 29691953
  7. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab 2018. PMC6185997
  8. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell 2015. PMC4693465
  9. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Commun Mass Spectrom 2019. PMID 30394592
  10. Cataldo LR, Fernandez-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med 2018. PMID 29593067
  11. Miller B, Kim SJ, Kumagai H, et al. Mitochondria-derived peptides in aging and healthspan. J Clin Invest 2022. PMC9057581
  12. Qin Q, Delrio S, Wan J, et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol 2018. PMID 29242099
  13. D'Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY) 2020. PMC7138593
  14. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol 2021. PMC12854548
  15. CohBar, Inc. A Phase 1a/1b study of safety, tolerability, and pharmacokinetics of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. ClinicalTrials.gov NCT03998514, study start 2018, completion 2021. NCT03998514
  16. Kim SJ, Miller B, Mehta HH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep 2019. PMC6640593
  17. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (category 2 of the bulk substances nominated under sections 503A or 503B). Web page, content current as of 22 April 2026. FDA category 2 page
  18. US Food and Drug Administration. Briefing document (introduction and points to consider), Pharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026. FDA briefing introduction
  19. Bascom E. FDA committee recommends looser restrictions for several peptides. Healio, 24 July 2026. Healio report
  20. Hudson Biotech. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity. ClinicalTrials.gov NCT07505745, 2026. NCT07505745